New Steroid-Based Treatment For Intraocular InflammationRecent developments in pharmaceuticals and technology now give us more choices for treating intraocular inflammation. Newer developments in eye drops now give us different “strengths” of steroid eye drops. New drug delivery systems will be giving us sustained release of steroids.

Steroid eye drops have been the mainstay of anti-inflammatory treatment for decades indicated for most types of ocular surgery and inflammatory conditions of the eye.

Intravitreal injections of triamcinolone acetonide (Kenalog) have been popular over the past several years. In this modality, the steroid is injected directly into the vitreous. Recently, FDA approved another new treatment – the Ozurdex. This drug is injected into the vitreous cavity and releases dexamethasone for a limited time. It is indicated for the treatment of macular edema caused by vein occlusions. The off-label use for intraocular inflammation is sure to follow for treatment of refractory uveitis and possible post-operative inflammation of the anterior segment and posterior segment (retina).